Severe acute respiratory syndrome coronavirus

Beroni Group Announces Successful Completion of SARS-CoV-2 Pseudovirus Neutralization Assay for Treatment of COVID-19

Monday, October 19, 2020 - 1:53pm

NEW YORK and SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (Beroni or the Company), an Australia-based diversified biopharmaceutical enterprise, today announces successful completion of SARS-CoV-2 pseudovirus neutralization assay in collaboration with GenScript Biotech Corporation (HKSE:1548) (GenScript), a leading global biotechnology company.

Key Points: 
  • NEW YORK and SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (Beroni or the Company), an Australia-based diversified biopharmaceutical enterprise, today announces successful completion of SARS-CoV-2 pseudovirus neutralization assay in collaboration with GenScript Biotech Corporation (HKSE:1548) (GenScript), a leading global biotechnology company.
  • On September 7, 2020, Beroni and Genscript performed an experiment to identify the most effective nanobodies.
  • Beroni aims at developing coronavirus-specific nanobodies as a treatment of COVID-19, which can be targeted on lung by aerosolization, rather than by intravenous drug administration.
  • The samples potency on neutralization were evaluated by performing SARS-CoV-2 pseudovirus neutralization assay.

Viral 'molecular scissor' is next COVID-19 drug target: Coronavirus uses enzymatic cutter for virus production and to disable essential immune proteins

Sunday, October 18, 2020 - 12:10pm

The researchers are from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and the Wroclaw University of Science and Technology.

Key Points: 
  • The researchers are from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and the Wroclaw University of Science and Technology.
  • Information gleaned by the American team helped Polish chemists to develop two molecules that inhibit the cutter, an enzyme called SARS-CoV-2-PLpro.
  • "It stimulates the release of proteins that are essential for the virus to replicate, and it also inhibits molecules called cytokines and chemokines that signal the immune system to attack the infection," Dr. Olsen said.
  • Visit our online Newsroom , and to see how we are battling COVID-19, read inspiring stories on Impact .

Eurofins Biomnis to Create Additional Capacity of 15,000 Tests Per Day Reported Within 24 Hours to Help Combat the Second Wave of the COVID-19 Pandemic

Friday, October 16, 2020 - 6:45am

In order to analyse the maximum number of samples in the shortest possible time, 1000 m2 of laboratory space, dedicated to SARS-CoV-2 tests, has been established.

Key Points: 
  • In order to analyse the maximum number of samples in the shortest possible time, 1000 m2 of laboratory space, dedicated to SARS-CoV-2 tests, has been established.
  • Since March, Eurofins Biomnis' testing capacity has been gradually ramped up to the point where it has now created spare capacity to test 15,000 samples per day in addition to its current volumes.
  • To meet demand, different teams work 24 hours a day, 7 days a week, which makes analyses validation possible even on Saturdays and Sundays.
  • Should the number of tests increase beyond current available capacity, Eurofins Biomnis can collaborate with other laboratories within the Eurofins Group.

Xi'an Jiaotong-Liverpool University researcher: COVID-19 coronavirus may have been pre-adapted to infect humans

Thursday, October 15, 2020 - 1:20pm

Bats' physiology is relatively unlike that of humans, so scientists have considered a direct jump, or "zoonotic leap" unlikely generally an animal virus needs to adapt to a human's body before infecting humans.

Key Points: 
  • Bats' physiology is relatively unlike that of humans, so scientists have considered a direct jump, or "zoonotic leap" unlikely generally an animal virus needs to adapt to a human's body before infecting humans.
  • Severe Acute Respiratory Syndrome (SARS) likely used civet cats in its path between bats and humans; Middle East Respiratory Syndrome (MERS) likely came from bats through camels to us.
  • However, a recent study implies the ancestors of the virus that causes COVID-19, SARS-CoV-2, may be predisposed to infect humans.
  • "'Nearly direct' means there is minimum evolution required for a SARS-CoV-2-like bat virus to jump to humans, which also implies the virus may be pre-adapted in bats to infect humans," he said.

Xi'an Jiaotong-Liverpool University researcher: COVID-19 coronavirus may have been pre-adapted to infect humans

Thursday, October 15, 2020 - 1:12pm

Bats' physiology is relatively unlike that of humans, so scientists have considered a direct jump, or "zoonotic leap" unlikely generally an animal virus needs to adapt to a human's body before infecting humans.

Key Points: 
  • Bats' physiology is relatively unlike that of humans, so scientists have considered a direct jump, or "zoonotic leap" unlikely generally an animal virus needs to adapt to a human's body before infecting humans.
  • Severe Acute Respiratory Syndrome (SARS) likely used civet cats in its path between bats and humans; Middle East Respiratory Syndrome (MERS) likely came from bats through camels to us.
  • However, a recent study implies the ancestors of the virus that causes COVID-19, SARS-CoV-2, may be predisposed to infect humans.
  • "'Nearly direct' means there is minimum evolution required for a SARS-CoV-2-like bat virus to jump to humans, which also implies the virus may be pre-adapted in bats to infect humans," he said.

Lactiga Announces NIH-Funded Partnership with Mount Sinai to Advance its Patented Biologic for COVID-19 Treatment

Wednesday, October 14, 2020 - 3:30pm

Lactiga Inc., a biotechnology company advancing its patented anti-infective biologic, LCTG-001, announced today a collaboration agreement with the Icahn School of Medicine at Mount Sinai to advance preclinical research into LCTG-001 as a potential treatment for COVID-19 patients.

Key Points: 
  • Lactiga Inc., a biotechnology company advancing its patented anti-infective biologic, LCTG-001, announced today a collaboration agreement with the Icahn School of Medicine at Mount Sinai to advance preclinical research into LCTG-001 as a potential treatment for COVID-19 patients.
  • We are proud to partner with Mount Sinai, which has maintained a leading role in COVID-19 research and innovation.
  • To date, preliminary in vitro studies demonstrate full neutralization of SARS-CoV-2 viral components, emphasizing the potential applicability of LCTG-001 to COVID-19 infections.
  • Lactiga has engaged the United States Food and Drug Administration through the Coronavirus Treatment Acceleration Program to optimize its transition from research toward first-in-human clinical testing.

America’s Top Young Scientist of 2020: 14-Year-Old Researches Spike Protein of SARS-CoV-2 Virus to Develop Novel Antiviral Drug to Combat Spread of COVID-19

Wednesday, October 14, 2020 - 1:05pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20201014005340/en/
    Anika Chebrolu named America's Top Young Scientist at this years 3M Young Scientist Challenge (Photo: 3M).
  • With the virus continuing to spread far and wide, there is an urgent need to find an effective anti-coronavirus drug.
  • In her study, Anika discovered a molecule that can selectively bind to the spike protein of the SARS-CoV-2.
  • Binding and inhibiting this viral protein would potentially stop the virus entry into the cell, creating a viable drug target.

RMA Paper Addresses Risks of Third Parties Working from Home, Returning to Offices During COVID-19

Tuesday, October 13, 2020 - 6:29pm

PHILADELPHIA, Oct. 13, 2020 /PRNewswire/ -- A new paper by The Risk Management Association (RMA) addresses the continuing risks posed by third parties of financial institutions as the COVID-19 pandemic evolves.

Key Points: 
  • PHILADELPHIA, Oct. 13, 2020 /PRNewswire/ -- A new paper by The Risk Management Association (RMA) addresses the continuing risks posed by third parties of financial institutions as the COVID-19 pandemic evolves.
  • "SARS-COV-2 Recommendations for Third Parties Working from Home and Returning to Facilities" will help institutions of all sizes mitigate the risks introduced by employees of third parties in these unprecedented times.
  • The paper offers detailed steps that allow financial institutions to uncover and address possible concerns related to third parties under four scenarios:
    transitioning from work-from-home to return-to-facilities.
  • To read RMA's "SARS-COV-2 Recommendations for Third Parties Working from Home and Returning to Facilities," click here.

DGAP-News: Formycon Receives Funding for COVID-19 Drug Research from the Bavarian Research Foundation

Tuesday, October 13, 2020 - 6:01am

Press Release // October 13, 2020

Key Points: 
  • Press Release // October 13, 2020
    Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has received a grant from the Bavarian Research Foundation for the project "Characterization of ACE2-lgG constructs" amounting to Euro 290,000.
  • SARS-CoV-2 requires the binding of the virus spike protein to the membrane angiotensin converting enzyme 2 (ACE2) for entry into the human host cell.
  • "We are very pleased about the positive assessment of our project by the Bavarian Research Foundation, which took place in an overly competitive environment.
  • With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines.

Alec Baldwin Backs New Invisi Smart Mask, Cutting Edge Technology, Endorsed By Clinical Test And Scientist That Kills 99.99% Of SARS CoV-2 Germs

Monday, October 12, 2020 - 7:45am

Alec and his brother Daniel Baldwin have done their homework and they have jointly decided to share the lifesaving InvisiSmart Mask & Shield with the world.

Key Points: 
  • Alec and his brother Daniel Baldwin have done their homework and they have jointly decided to share the lifesaving InvisiSmart Mask & Shield with the world.
  • InvisiSmart is an engineered next-generation solution that kills 99.99% of SARS CoV-2 germs.
  • InvisiSmart technology is verified by robust laboratory and clinical evidence, and comes as a Mask, Shield Spray, Seat Covers, and Sanitizer.
  • InvisiSmart Technologies has been proven to destroy the COVID-19 spike virus by the University of Cambridge.